Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of $173.64 billion. The enterprise value is $187.94 billion.
| Market Cap | 173.64B |
| Enterprise Value | 187.94B |
Important Dates
The next confirmed earnings date is Wednesday, November 4, 2026, before market open.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | Aug 17, 2026 |
Share Statistics
Novo Nordisk has 4.43 billion shares outstanding. The number of shares has decreased by -0.14% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.43B |
| Shares Change (YoY) | -0.14% |
| Shares Change (QoQ) | -0.29% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 27.65% |
| Float | 3.17B |
Valuation Ratios
The trailing PE ratio is 9.76 and the forward PE ratio is 11.77.
| PE Ratio | 9.76 |
| Forward PE | 11.77 |
| PS Ratio | 3.45 |
| Forward PS | 0.57 |
| PB Ratio | 5.14 |
| P/TBV Ratio | 11.45 |
| P/FCF Ratio | 15.24 |
| P/OCF Ratio | 8.77 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.08, with an EV/FCF ratio of 16.50.
| EV / Earnings | 10.56 |
| EV / Sales | 3.73 |
| EV / EBITDA | 7.08 |
| EV / EBIT | 7.62 |
| EV / FCF | 16.50 |
Financial Position
The company has a current ratio of 0.87, with a Debt / Equity ratio of 0.63.
| Current Ratio | 0.87 |
| Quick Ratio | 0.64 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | 0.80 |
| Debt / FCF | 1.88 |
| Interest Coverage | 1,566.84 |
Financial Efficiency
Return on equity (ROE) is 59.82% and return on invested capital (ROIC) is 39.22%.
| Return on Equity (ROE) | 59.82% |
| Return on Assets (ROA) | 18.73% |
| Return on Invested Capital (ROIC) | 39.22% |
| Return on Capital Employed (ROCE) | 45.35% |
| Weighted Average Cost of Capital (WACC) | 5.67% |
| Revenue Per Employee | $724,276 |
| Profits Per Employee | $256,008 |
| Employee Count | 69,505 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.22 |
Taxes
In the past 12 months, Novo Nordisk has paid $4.94 billion in taxes.
| Income Tax | 4.94B |
| Effective Tax Rate | 21.72% |
Stock Price Statistics
The stock price has decreased by -27.63% in the last 52 weeks. The beta is 0.38, so Novo Nordisk's price volatility has been lower than the market average.
| Beta (5Y) | 0.38 |
| 52-Week Price Change | -27.63% |
| 50-Day Moving Average | 42.36 |
| 200-Day Moving Average | 44.94 |
| Relative Strength Index (RSI) | 47.25 |
| Average Volume (20 Days) | 11,812,239 |
Short Selling Information
The latest short interest is 31.62 million, so 1.00% of the outstanding shares have been sold short.
| Short Interest | 31.62M |
| Short Previous Month | 31.65M |
| Short % of Shares Out | 1.00% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.34 |
Income Statement
In the last 12 months, Novo Nordisk had revenue of $50.34 billion and earned $17.79 billion in profits. Earnings per share was $4.00.
| Revenue | 50.34B |
| Gross Profit | 41.27B |
| Operating Income | 24.66B |
| Pretax Income | 22.73B |
| Net Income | 17.79B |
| EBITDA | 26.54B |
| EBIT | 24.66B |
| Earnings Per Share (EPS) | $4.00 |
Balance Sheet
The company has $6.87 billion in cash and $21.41 billion in debt, with a net cash position of -$14.54 billion or -$3.28 per share.
| Cash & Cash Equivalents | 6.87B |
| Total Debt | 21.41B |
| Net Cash | -14.54B |
| Net Cash Per Share | -$3.28 |
| Equity (Book Value) | 33.81B |
| Book Value Per Share | 7.64 |
| Working Capital | -4.64B |
Cash Flow
In the last 12 months, operating cash flow was $19.81 billion and capital expenditures -$8.42 billion, giving a free cash flow of $11.39 billion.
| Operating Cash Flow | 19.81B |
| Capital Expenditures | -8.42B |
| Depreciation & Amortization | 1.85B |
| Net Borrowing | 5.47B |
| Free Cash Flow | 11.39B |
| FCF Per Share | $2.57 |
Margins
Gross margin is 81.99%, with operating and profit margins of 48.99% and 35.35%.
| Gross Margin | 81.99% |
| Operating Margin | 48.99% |
| Pretax Margin | 45.15% |
| Profit Margin | 35.35% |
| EBITDA Margin | 52.72% |
| EBIT Margin | 48.99% |
| FCF Margin | 23.02% |
Dividends & Yields
This stock pays an annual dividend of $1.28, which amounts to a dividend yield of 3.26%.
| Dividend Per Share | $1.28 |
| Dividend Yield | 3.26% |
| Dividend Growth (YoY) | 4.13% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 32.01% |
| FCF Payout Ratio | 49.83% |
| Buyback Yield | 0.14% |
| Shareholder Yield | 3.40% |
| Earnings Yield | 10.25% |
| FCF Yield | 6.56% |
Analyst Forecast
The average price target for Novo Nordisk is $45.80, which is 16.39% higher than the current price. The consensus rating is "Hold".
| Price Target | $45.80 |
| Price Target Difference | 16.39% |
| Analyst Consensus | Hold |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 1.56% |
| EPS Growth Forecast (3Y) | 1.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 20, 2023. It was a forward split with a ratio of 2:1.
| Last Split Date | Sep 20, 2023 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novo Nordisk has an Altman Z-Score of 4.21 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.21 |
| Piotroski F-Score | 5 |